|
Jun 13
|
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
|
|
Jun 5
|
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?
|
|
Jun 4
|
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
|
|
Jun 3
|
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
|
|
Apr 25
|
Beam Therapeutics to Report Q1 Earnings: What's in the Cards?
|
|
Apr 21
|
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
|
|
Mar 14
|
Biotech Alert: Searches spiking for these stocks today
|
|
Mar 11
|
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
|
|
Mar 10
|
Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now?
|
|
Mar 10
|
Beam Therapeutics Says Initial Data Show BEAM-302 Increases Alpha-1 Antitrypsin Protein
|
|
Mar 10
|
Beam Therapeutics Announces Pricing of Underwritten Offering
|
|
Mar 10
|
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
|
|
Feb 24
|
Cathie Wood buys $11 million of under-the-radar AI stock
|
|
Feb 24
|
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
|
|
Feb 23
|
Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025
|
|
Feb 21
|
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 13
|
Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High?
|
|
Feb 10
|
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?
|
|
Dec 30
|
Why Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In?
|
|
Dec 29
|
Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?
|